About

Axel Bex is a leading urologic oncologist whose research has fundamentally shaped the management of kidney and prostate cancers. His work centers on optimizing surgical precision and personalizing treatment, particularly through the advancement of robotic-assisted techniques and nephron-sparing strategies. Bex’s seminal contribution is his authorship of the ESMO Clinical Practice Guidelines for renal cell carcinoma, a globally cited framework with over 500 references that standardizes diagnosis and treatment. He has pioneered the use of stereotactic radiosurgery for renal tumors and led the NEST feasibility trial, a landmark study comparing percutaneous cryoablation to robotic partial nephrectomy for small renal masses. Beyond kidney cancer, Bex has refined prostate cancer surgery, notably by using quantitative assessments of fascia preservation and intraoperative ultrasound to improve continence outcomes after robotic prostatectomy. His work on sentinel lymph node dissection has also advanced the selection of node-negative prostate cancer patients for pelvic radiation. With a portfolio of highly cited papers and a focus on high-level evidence, Bex is a key figure in the shift toward minimally invasive, function-preserving oncology.

Research Focus

Key Achievements

12
H-Index
23
Papers
924
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
514 citations · 2016
📈 Most Prolific Year: 2022 (4 Papers)
🤝 Key Collaborators: 188
🏛 Institutions: The Netherlands Cancer Institute, The Royal Free Hospital, Royal Free London NHS Foundation Trust, University College London

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago